Evaro closes €21 million round to scale embedded health services
Digital health startup Evaro has raised €21 million to accelerate the rollout of its NHS-licensed embedded health services, partnering with femtech pioneer Clue and sexual wellness brand Lovehoney. The fresh capital will support the expansion of clinically validated sexual and reproductive health offerings directly inside consumer platforms and partner ecosystems.
Embedding NHS-licensed care into everyday digital journeys
Evaro focuses on integrating sexual health, reproductive health and broader preventive care into apps and online services that people already use. By building embedded health services into partners’ digital journeys, users can access evidence-based medical pathways, testing, and treatment without leaving familiar platforms.
The partnership with Clue, a leading menstrual and fertility tracking app, will allow users to connect cycle data with clinical-grade assessments and access to UK NHS-licensed services. Collaboration with Lovehoney brings discreet, clinically informed sexual health support to a global e‑commerce audience that is already engaged with intimacy and wellbeing products.
Addressing gaps in sexual and reproductive healthcare
Across Europe, demand for sexual health services is rising while public systems face capacity constraints and long waiting times. Evaro aims to reduce friction by enabling users to book tests, receive remote consultations and access prescriptions through a digital-first care model that is designed to meet NHS quality and safety standards.
The new funding will be channelled into scaling clinical operations, expanding telehealth infrastructure, and deepening integrations with consumer brands that reach younger, often underserved demographics. The company is also expected to invest in data security and regulatory compliance to ensure that cross-border services remain aligned with UK and EU health regulations.
Positioning for the next wave of digital health
By combining consumer reach from partners such as Clue and Lovehoney with NHS-licensed clinical pathways, Evaro is positioning itself at the intersection of digital health, femtech and sexual wellness. The €21 million round signals growing investor confidence in models that bring regulated healthcare directly into everyday digital experiences, rather than expecting patients to navigate fragmented systems on their own.